Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HF50
- Development stage
- Phase 1
- Lead developer
- HighField Biopharmaceuticals
- Modality
- Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HF50 is an investigational **liposomal T-cell engager** developed by HighField Biopharmaceuticals for advanced HER2-positive and HER2-low solid tumors. The lipid nanoparticle displays anti-CD3ε and anti-HER2 antibody fragments to bridge T cells to HER2-expressing tumor cells, while encapsulating an undisclosed Toll-like receptor 7/8 agonist intended to activate myeloid cells and augment antitumor immunity. It is administered by weekly intravenous infusion with step-up dosing in ongoing first-in-human Phase 1 studies. Early clinical data in a small salivary-gland-cancer cohort reported manageable toxicity and preliminary antitumor activity. ([jitc.bmj.com](https://jitc.bmj.com/content/13/Suppl_3/A1550))
- Other names
- HF-50HF50HF 50
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on HF50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HF50.